

CLINICAL RESEARCH

newsletter



July 2026

IMPORTANT INFO:

Year 13 begins August 1: starting the year together

As we begin a new NCORP program year on August 1, early planning and communication can help position your site for success. While every site's priorities and timelines are different, focusing on a few key operational areas early in the year can help reduce challenges later and keep studies moving forward.

Four areas will make the biggest difference right now:

Study Activation: Working through regulatory approvals, site rosters, and other activation requirements early can help ensure studies are ready to enroll patients as soon as possible.

Identifying Enrollment Opportunities: Consistent screening helps ensure eligible patients have the opportunity to participate in clinical trials while supporting the network's mission of expanding access to research.

Data Quality: Timely data entry and prompt query resolution help maintain data quality, reduce reconciliation efforts, and support protocol compliance throughout the study.

Follow-up: Maintaining current survival and long-term follow-up information protects the integrity of study data and remains an important focus during audits.

Georgia CORE is committed to supporting your team throughout the program year. Whether you're working through study activation, recruitment challenges, data management, or other operational questions, we're here to partner with you and help identify solutions. Please don't hesitate to reach out.


TABLE OF CONTENTS

TOPIC	PAGE
Important Info	1
Research Base RoundUp	2
CORE Fundamentals/NCORP News	3
Did you know/Reminders/Pending Tx	4
Recently Activated Trials	5
Open CCDR Studies	6
NCORP Crossword Puzzle	7



WF-2502CD - STOP-VTE - Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network

We will be wrapping up Part I of this study in the coming months and are asking that you complete all Step 1 enrollments for your providers by September 1, 2026. If you plan to open this study at your site, please reach out to ncorp@wfusm.edu for Start-up information as soon as possible; Subject line: WF-2502CD.



CLINICAL RESEARCH

newsletter



July 2026

RESEARCH BASE ROUNDUP

SWOG.

Fifteen-year follow-up from the S0016 trial in follicular lymphoma, published in JAMA Oncology, suggests the disease may be functionally curable for many patients. Relapse risk fell sharply over time, from about 6.8 percent in the first five years to under 1 percent between years 15 and 20, and roughly 70 percent of patients remained alive at 15 years. It is a strong reminder of why long-term follow-up data matter. SWOG's S2409 (PRISM) in extensive-stage small cell lung cancer also continues to enroll.

NRG ONCOLOGY.

NRG-GU005 reported that stereotactic body radiation therapy improved bowel-related quality of life versus moderately hypofractionated IMRT in localized intermediate-risk prostate cancer. The COMMIT study (NRG-GI004/SWOG-S1610) also reported out, a good example of cross-group collaboration on colorectal cancer.

URCC NCORP RESEARCH BASE.


The University of Rochester Cancer Center research base, with 35-plus years in symptom science and cancer care delivery research, remains a go-to for supportive care and geriatric oncology trials, areas where community sites can accrue steadily alongside treatment studies.

ECOG-ACRIN.

The phase III ENDURANCE (E1A11) trial was published in the New England Journal of Medicine in July 2026, with Emory Winship's Dr. Sagar Lonial among the authors. It found that two years of lenalidomide maintenance gave the same long-term survival benefit as indefinite treatment to progression in multiple myeloma, a meaningful quality-of-life finding for patients. The group also presented brain tumor, breast, kidney, lung, and Merkel cell results across ASCO and SNMMI 2026.

WAKE FOREST NCORP RESEARCH BASE.

Wake Forest continues to lead cancer control and care delivery studies well suited to community sites, including COSMIC (WF-2304), assessing benefits and harms of cannabis and cannabinoid use, and WF-2303CD on health-related social needs screening. Worth noting: their accrual year, like ours, runs August 1 through July 31, so their calendar mirrors our Year 13 window.



CLINICAL RESEARCH

newsletter



July 2026

TRIAL CONDUCT REMINDERS

- Consent first, always: no study procedure before the current IRB-approved consent is signed and dated. Re-consent when a new version is approved.
- Verify against source: every data point in the EDC must trace to a source document. If it isn't documented, it didn't happen.
- Enter and resolve promptly: meet protocol data-entry timelines and close queries quickly, before they pile up ahead of a monitoring visit.
- Keep regulatory current: delegation logs, training records, and 1572s should reflect who is actually doing the work today.
- Report events on time: SAEs and deviations have clocks. Know your protocol's reporting windows and hit them.

DID YOU KNOW?


- SWOG trials alone have contributed to the FDA approval of 14 cancer drugs and changed more than 100 standards of care.
- NCORP's roots reach back to 1983, when the NCI launched the Community Clinical Oncology Program (CCOP) to bring research to community physicians. It was reorganized into today's NCORP in 2014.
- URCC was the first NCI-funded CCOP research base ever housed within a cancer center.
- The classic CHOP chemotherapy regimen packs four drugs into one acronym: cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine, and prednisone.

TRIALS PENDING ACTIVATION

Research Base	Title
ECOG-ACRIN	EAQ241CD: FinFit: Addressing Financial Hardship in AYA Cancer Survivors
	EAQ181: Randomized Controlled Trial of FoRtitude: Targeted eHealth Intervention to Reduce Fear of Recurrence Among Breast Cancer Survivors in Community Oncology Settings
	EAQ161CD: Biomarker Testing in Common Solid Cancers: An Assessment of Current Practices in Precision Oncology in the Community Setting
Alliance	A222302: Family Communications After Genetic Testing

CLINICAL RESEARCH

newsletter



July 2026

RECENTLY ACTIVATED TREATMENT TRIALS

Research Base	Title	CTSU Activation Date
SWOG	S2419: Phase III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]	4/22/2026
	S2504: A Randomized Phase III Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Participants with Previously Untreated Richter Transformation (PIRAMID)	6/1/2026
	SN2426: A Randomized Phase II Study of Amivantamab (JNJ-61186372) and Hyaluronidase (rHuPH20) Versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma	7/9/2026
	S2505: Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Hypofractionated Radiation (UHRT-5) Versus Standard Fractionation (RT-25) for Stage II-IIIIB, Extremity, Resectable Soft Tissue Sarcoma	7/6/2026
ECOG	EA1242: A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer with RS	5/20/2026
NRG	NRG-HN016: Radiotherapy with Concurrent Cetuximab vs. Carboplatin and Paclitaxel in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin: A Pragmatic Phase III Randomized Trial (CONCISE)	6/10/2026
	NRG-CC017: A Randomized Phase III Study Comparing Temporally-Modulated Pulsed Radiation Therapy (TMPRT) Versus Standard Radiation Therapy with Temozolomide for Adults with Newly Diagnosed MGMT-Unmethylated Glioblastoma	4/1/2026
	NRG-GY026: A Phase III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma	7/1/2026
Alliance	MM1YA-A04: Phase II Study of Cytarabine + Daunorubicin (7 + 3) + Gemtuzumab Ozogamicin vs. Cytarabine + Daunorubicin (7 + 3) + Venetoclax for the Treatment of Newly Diagnosed Core Binding Factor Acute Myeloid Leukemia (CBF-AML) in Younger Adults: A MyeloMATCH Substudy	5/8/2026
	A082402: Involved-Station, Intensity-Modulated Post-Operative Radiation Therapy (I ² -PORT) for Resected Non-Small Cell Lung Cancer with Residual Mediastinal Adenopathy After Neoadjuvant Therapy (ypN2)	5/1/2026
	A062101: A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination with Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma	6/12/2026

CLINICAL RESEARCH

newsletter



July 2026

OPEN AND ENROLLING CANCER CARE DELIVERY RESEARCH TRIALS

Research Base	Title	CTSU Activation Date
Alliance	A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients	9/26/2025
	A232402CD: PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays	1/06/2026
ECOG-ACRIN	EAQ222CD: Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) Sites must receive approval prior to initiating any study start-up activities.	2/29/2024
SWOG	S2417CD: A Pragmatic Randomized Controlled Trial To Evaluate The Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance	8/4/2025
	S2424CD: A Randomized Controlled Trial of an Intervention called "Algorithm-Enabled Patients Activated in Cancer Care through Teams" (A-PACT) to Improve Goals of Care Communication for People with Cancer	6/1/2026
Wake Forest	WF-2301CD: Multi-site Community Oncology Planning for the CONNECT Intervention Targeting Lung Cancer Caregivers ² Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.	7/2/2024
	WF-2501CD: Practical Delivery of Geriatric Assessment in Community Oncology Settings (PGA)	12/2/2025
	WF-2402CD: Collaborative Oncology between Radiologists and Radiation Oncologists for the Evaluation of Contoured Targets (CORRECT)	2/20/2026
	WF-2502CD: Surgical Thromboprophylaxis Practices in Oncology Patients within the NCORP Network (STOP-VTE)	12/02/2025

CLINICAL RESEARCH

newsletter



July 2026

UPCOMING RESEARCH BASE MEETINGS*

Research Base	Date	Location
SWOG	October 9-11, 2026	Chicago, IL
	April 15-17, 2027	San Francisco, CA
	October 14-16, 2027	Chicago, IL
ECOG	October 20 - 22, 2026	Philadelphia, PA
	May 4-6, 2027	Baltimore, MD
	October 26-28, 2027	Chicago, IL
URCC	September 10-12, 2026	Niagara Falls, NY
Wake Forest	October 12-14, 2026	Myrtle Beach, SC
NRG	January 28-30, 2027	Las Vegas, NV
	July 15-17, 2027	Washington, DC

UPCOMING ROUTINE AUDITS¹

ECOG	TBD	Exact dates and method (onsite vs virtual) are pending.
NRG	TBD	
SWOG	TBD for 2027	
URCC	TBD for 2027	
Wake Forest	TBD for 2027	

*Please contact Shantoria Brown (sbrown@georgiacore.org)
to discuss travel funds.

SAVE the DATE

FOR THE
INVESTIGATORS AND ADMINISTRATORS MEETING

DATE
Thursday, August 20, 2026

TIME
5:00 PM – 8:00 PM

LOCATION
Alpharetta Conference Center
5000 Avalon Blvd, Alpharetta, GA 30009

Collaborating today for
a stronger tomorrow.

INVESTIGATE. COLLABORATE. IMPACT.


CLINICAL RESEARCH

newsletter



July 2026

NCORP CROSSWORD



The first person to answer correctly will receive Georgia NCORP swag and a shout-out in the next issue! Send your responses to kdixon@georgiacore.org.



ACROSS

1. Subject enrollment onto a trial; the number that keeps a site viable
5. NCI Community Oncology Research Program (acronym)
7. ECOG-ACRIN myeloma maintenance trial (E1A11) published in NEJM in July 2026
10. The document governing how a trial is conducted
11. Wake Forest's COSMIC study weighs benefits and harms of _____ in cancer patients
13. Cooperative group whose S0016 follicular lymphoma trial reported 15-year results
14. Board that reviews and approves human subjects research (acronym)

DOWN

2. Informed _____ must be documented before any study procedure
3. URCC research base is at the University of _____
4. _____ documents are the original records data entry is verified against
6. A data _____ is a request to resolve a discrepancy in the database
8. Continued data collection after treatment ends; the last of accrual, entry, and _____
9. Person who reviews site data and regulatory files for compliance
12. Oncology group known for GU, GI, breast, and prostate radiation trials